Skip to Main Content (Press Enter)

Logo UNITO
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione

UNI-FIND
Logo UNITO

|

UNI-FIND

unito.it
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione
  1. Pubblicazioni

Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin

Articolo
Data di Pubblicazione:
2024
Abstract:
Background: Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent use of rifampicin and protease inhibitors. We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin. Methods: DERIVE (NCT04121195, EDCTP) was a dose-escalation trial in people with HIV on atazanavir/ritonavir-based ART in Uganda. Four intensive pharmacokinetic (PK) visits were performed: PK1 300/100 mg OD (baseline); PK2 300/100 mg OD with rifampicin 600 mg; PK3 300/100 mg BID with rifampicin 600 mg OD; PK4 300/100 mg BID with rifampicin 1200 mg OD. Dolutegravir 50 mg BID throughout the study period ensured participants remained protected from subtherapeutic atazanavir concentrations. The data was interpreted with noncompartmental analysis. The target minimum concentration was atazanavir's protein-adjusted IC90 (PA-IC90), 0.014 mg/L. Results: We enrolled 26 participants (23 female) with median (range) age 44 (28-61) years and weight 67 (50-75) kg. Compared with PK1, atazanavir Ctau, and AUC were significantly reduced at PK2 by 96% and 85%, respectively. The escalation to BID dosing (PK3) reduced this difference in Ctau, and AUC24 to 18% lower and 8% higher, respectively. Comparable exposures were maintained with double doses of rifampicin. Lowest Ctau during PK1, PK3, and PK4 were 12.7-, 4.8-, and 8.6-fold higher than PA-IC90, respectively, while 65% of PK2 Ctau were below the limit of quantification (0.03 mg/L), hence likely below PA-IC90. No participant developed significant elevation of liver enzymes, reported an SAE, or experienced rebound viraemia. Conclusions: Twice daily atazanavir/ritonavir during rifampicin co-administration was well-tolerated and achieved plasma concentrations above the target.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Africa CID specifications; HIV; Tuberculosis; atazanavir; drug-drug interaction; pharmacokinetics; rifampicin
Elenco autori:
Gausi, Kamunkhwala; Mugerwa, Henry; Siccardi, Marco; Montanha, Maiara Camotti; Lamorde, Mohammed; Wiesner, Lubbe; D'Avolio, Antonio; McIlleron, Helen; Wilkins, Ed; De Nicolo, Amedeo; Maartens, Gary; Khoo, Saye; Kityo, Cissy; Denti, Paolo; Waitt, Catriona
Autori di Ateneo:
D'AVOLIO Antonio
DE NICOLO' Amedeo
Link alla scheda completa:
https://iris.unito.it/handle/2318/1951990
Pubblicato in:
CLINICAL INFECTIOUS DISEASES
Journal
Progetto:
PROGETTO H2020 VirTUAL :VULNERABLE POPULATION TUBERCULOSIS ANTIRETROVIRAL" PROF. D'AVOLIO
  • Aree Di Ricerca

Aree Di Ricerca

Settori (14)


LS7_7 - Pharmacology and toxicology - (2022)

CIBO, AGRICOLTURA e ALLEVAMENTI - Farmacologia Veterinaria

CIBO, AGRICOLTURA e ALLEVAMENTI - Patologia e malattie degli animali

CIBO, AGRICOLTURA e ALLEVAMENTI - Scienze cliniche veterinarie

MEDICINA, SALUTE e BENESSERE - Disturbi neuropsichiatrici

MEDICINA, SALUTE e BENESSERE - Epidemiologia

MEDICINA, SALUTE e BENESSERE - Malattie neurologiche e neurodegenerative

MEDICINA, SALUTE e BENESSERE - Medicina Rigenerativa e Cellule Staminali

MEDICINA, SALUTE e BENESSERE - Oncologia e Tumori

MEDICINA, SALUTE e BENESSERE - Ricerca Traslazionale e Clinica

MEDICINA, SALUTE e BENESSERE - Trapianti e medicina rigenerativa

SCIENZE DELLA VITA e FARMACOLOGIA - Interazioni tra molecole, cellule, organismi e ambiente

SCIENZE DELLA VITA e FARMACOLOGIA - Molecole bioattive

SCIENZE DELLA VITA e FARMACOLOGIA - Sviluppo del sistema nervoso e plasticità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.6.1.0